OPL.ASX
Opyl’s TrialKey Platform to be Used as Exclusive Agent in Tracking Success Of Clinical Biotech Trials
Opyl (ASX: OPL) has signed a services agreement with UK-based Innovatrix Capital formalising commercial terms for Opyl’s proprietary platform TrialKey to act as an exclusive calculation agent in Innovatrix’s clinical trial failure insurance products. TrialKey is an AI-powered decision support tool that predicts the probability of success for clinical trials and helps sponsors optimise trial […]
Opyl divests subsidiary Opin to focus on development of AI clinical trial platform
Opyl (ASX: OPL) will divest its clinical trial recruitment subsidiary Opin to an entity controlled by global health technology entrepreneur Dr Hugo Stephenson. Under the terms of the agreement, a nominal $1 cash purchase price will ensure Opyl retains a 20% ownership stake in Opin via its interest in Trial Screen. As part of the […]
Opyl unveils AI platform capable of forecasting COVID-19 clinical trial success
Opyl (ASX: OPL) has unveiled software that harnesses artificial intelligence (AI) to calculate a probability of success for pharmaceutical companies currently developing vaccines, drugs and medical devices in clinical trials. Importantly, the new AI platform will be able to assist companies in developing drugs and vaccines as part of existing COVID-19 trials. Opyl claims it […]
